Print Page | Sign In | Join
Business Wire Life Sciences News (US)
Share |

Tesseract Ventures Launches PRISM to Create Safer Work Environments During COVID-19Open in a New Window

KANSAS CITY, Mo.--(BUSINESS WIRE)--Tesseract Ventures today announced the launch of its new product, Tesseract PRISM™.

 

CloudNine New Account Sales Surge to Record High, Bolstered by Growing Partner Network and New Technology InnovationOpen in a New Window

HOUSTON--(BUSINESS WIRE)-- #CloudNine--eDiscovery tech company CloudNine set a company record for new sales bookings in April. Recent months have been transformational for the company.

 

Triplet Therapeutics Initiates SHIELD HD Natural History Study of Huntington’s DiseaseOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Triplet Therapeutics, Inc. announced today it has initiated a natural history study of Huntington’s disease (HD) called SHIELD HD.

 

Learn from Specialty Rx Experts: 1st Episode of AscellaHealth Educational Webinar Series “Specialty Market Trends and the Market Place Realities for Pharmacy Benefit Managers”Open in a New Window

BERWYN, Pa.--(BUSINESS WIRE)--Learn from Specialty Rx Experts: 1st Episode of AscellaHealth Educational Webinar Series

 

Multi Radiance Medical Announces Start of Non-Pharmaceutical Clinical Trial Using Photobiomodulation to Treat Intubated COVID-19 PatientsOpen in a New Window

SOLON, Ohio--(BUSINESS WIRE)--Researchers are conducting a clinical trial using Multi Radiance Medical photobiomodulation technology to improve critical care in COVID-19 patients.

 

Tetraphase Announces Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased ConsiderationOpen in a New Window

WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection) to treat serious and life-threatening infections, today announced that it has entered into an amendment to the Agreement and Plan of Merger, dated March 15, 2020, to which the Company is a party with AcelRx Pharmaceuticals, Inc. (“AcelRx”) and its merger subsidiary (the “Merger Agreement”), to increa

 

Fidelis Specialty Pharmacy Earns URAC Specialty Pharmacy AccreditationOpen in a New Window

ARCADIA, Calif.--(BUSINESS WIRE)--Latino-owned specialty pharmacy Fidelis earned URAC’s specialty pharmacy accreditation, demonstrating its commitment to best-in-class patient services

 

Level Ex® Releases Video Game COVID-19 Levels to Prepare Healthcare ProvidersOpen in a New Window

CHICAGO--(BUSINESS WIRE)--Level Ex has launched COVID-19 levels within its Airway Ex and Pulm Ex mobile games.

 

Northwell Direct Offers COVID-19 Testing, Suite of Health Care Services for New York EmployersOpen in a New Window

NEW HYDE PARK, N.Y.--(BUSINESS WIRE)--Northwell Health has launched a new company, Northwell Direct, to provide New York employers with a customizable suite of health and wellness services, including a range of COVID-related offerings. The launch comes as employers throughout New York prepare to reopen based on the phased approach outlined by Governor Cuomo. Businesses are looking for a reliable way to keep their employees safe, yet lack the expertise that Northwell can bring to meet their need

 

Maverick Therapeutics to Participate at 2020 Jefferies Virtual Healthcare ConferenceOpen in a New Window

BRISBANE, Calif.--(BUSINESS WIRE)--Maverick Therapeutics Inc., a private biopharmaceutical company pioneering conditionally active bispecific T cell targeted immunotherapies, today announced it will share company and pipeline updates at the Jefferies Virtual Healthcare Conference being held from June 2 to June 4, 2020. Chief Executive Officer Jim Scibetta is scheduled to participate in a live presentation on June 3, 2020 at 3:30 p.m. Eastern Time. Following the conference, the presentation will

 

Research Reveals Health System and Health Plan Misperceptions Inhibit Patient-Centered Specialty Pharmacy PartnershipsOpen in a New Window

ATLANTA--(BUSINESS WIRE)-- #healthcaresavings--Today, Trellis Rx, a technology-enabled specialty pharmacy services provider, published a qualitative study that offers new insight into why health system specialty pharmacies often struggle to partner with payors. The study found that misperceptions about health system specialty pharmacies’ capabilities, outcomes and pricing often pigeonhole them into being seen as expensive providers of a “commodity” services by payors. Additionally, the study revealed opportunities

 

Altapure’s Technology Achieves High Level Disinfection of N95 Safety MasksOpen in a New Window

MEQUON, Wis.--(BUSINESS WIRE)--Altapure, LLC, an innovative technology and manufacturing company dedicated to providing high-level disinfection products to medical and long-term care facilities, today announced new data evaluating two of its devices for the disinfection of personal protective equipment (PPE). Two studies demonstrated the effectiveness of the company’s ultrasonic disinfection technology for the rapid decontamination of large numbers of N95 respirators. Both products generate sub

 

Circle Pharma Appoints William G. Kaelin Jr. MD as Chair of Its Scientific Advisory BoardOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma has appointed 2019 Nobel Laureate William G. Kaelin Jr., MD as its lead science advisor and chair of its SAB.

 

Azitra Announces Rare Pediatric Disease Designation for ATR-12 for the Treatment of Netherton SyndromeOpen in a New Window

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra receives Rare Pediatric Disease Designation for ATR-12 for Netherton syndrome, a chronic genetic skin disease.

 

FDA Accepts for Review Fresenius Kabi’s BLA Submission for Pegfilgrastim BiosimilarOpen in a New Window

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, announced today the U.S. Food and Drug Administration has accepted for review the company’s Biologics License Application (BLA) for MSB11455, the company’s pegfilgrastim biosimilar candidate for Neulasta®. This is Fresenius Kabi’s first U.S. biosimilar regulatory submission. Pegfilgrastim is used to reduce the incidence

 

Centricity Vision Introduces New Name and Leadership TeamOpen in a New Window

CARLSBAD, Calif.--(BUSINESS WIRE)--Centricity Vision today announced a new executive leadership team, along with a new company name.

 

IFM Announces Tracy W. Gaudet, MD, as Closing Keynote at 2020 Annual International ConferenceOpen in a New Window

FEDERAL WAY, Wash.--(BUSINESS WIRE)--The Institute for Functional Medicine (IFM) today announced Tracy W. Gaudet, MD, as the closing keynote speaker for IFM’s Annual International Conference (AIC) 2020: Advancements in Clinical Research and Innovative Practices in Functional Medicine. Dr. Gaudet is the founding executive director of the Veterans Health Administration’s (VHA) National Office of Patient Centered Care and Cultural Transformation. She led the VHA’s transition to Whole Health, a uni

 

MEDITECH’s 2020 Nurse Forum Goes VirtualOpen in a New Window

WESTWOOD, Mass.--(BUSINESS WIRE)-- #EHR--As nurses continue to work tirelessly to provide care throughout the current pandemic, MEDITECH is offering support to the community virtually. Due to COVID-19, the company is announcing it will host its 2020 Nurse Forum: Lighting the Way Through Innovation for the nursing community online for the first time. The virtual event will take place on June 17-19th, from 11:30 a.m. - 3:00 p.m. EST. Join as MEDITECH highlights the company’s Expanse solutions and custom

 

Veracyte to Present at the William Blair 40th Annual Growth Stock ConferenceOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Present at the William Blair 40th Annual Growth Stock Conference

 

Sensei Biotherapeutics Completes Acquisition of Alvaxa Biosciences, a Camelid Antibody Therapeutics CompanyOpen in a New Window

GAITHERSBURG, Md. & BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the acquisition of Alvaxa Biosciences, Inc., a camelid antibody therapeutics company with technology licensed from Fred Hutchinson Cancer Research Center. Under the terms of the agreement, Sensei will acquire Alvaxa Biosciences and its existing camelid nanobody libraries, expertise in nanobody discovery, as well as

 

Axial Biotherapeutics to Present at the Jefferies Virtual Global Healthcare ConferenceOpen in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)--Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the David H. Donabedian, Ph.D., Co-founder and Chief Executive Officer of Axial Biotherapeutics will present a company overview at the Jefferies Virtual Global Healthcare Conference on Wednesday, June 3, 2020 at 4:30 PM ET. About Axial Biotherapeutics Axial Biotherapeuti

 

Ironwood and AbbVie Report Top-line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with Irritable Bowel Syndrome with Diarrhea (IBS-D)Open in a New Window

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced top-line data from a Phase II trial evaluating MD-7246 in adult patients with abdominal pain associated with irritable bowel syndrome with diarrhea (IBS-D). The Phase II trial did not meet its primary or key secondary endpoints. Based on these findings, Ironwood and AbbVie plan to discontinue the development of MD-7246. Results from a previously announced MD-7246 Phase II tri

 

Deerfield Commits Up to $130 Million to Commercialize Drug Discovery at University of MichiganOpen in a New Window

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--Deerfield Commits Up to $130 Million to Commercialize Drug Discovery at the University of Michigan.

 

BioDot Accelerates Manufacturing to Help Customers Meet Global COVID-19 Testing DemandOpen in a New Window

IRVINE, Calif.--(BUSINESS WIRE)--Automated “lateral flow” dispensing technology is vital step in rapid point-of-care antibody test production

 

Kinnate Biopharma Appoints Nima Farzan as Chief Executive OfficerOpen in a New Window

SAN DIEGO, Calif.--(BUSINESS WIRE)-- #biotechnology--Kinnate expands its executive leadership team with the appointment of Nima Farzan as CEO and Mark Meltz as COO and General Counsel

 

Frequency Therapeutics to Present at Upcoming Investor ConferencesOpen in a New Window

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a company overview at the Jefferies Virtual Healthcare Conference and participate in a “fireside chat” at the Goldman Sachs Annual Global Healthcare Conference. Details for each eve

 

Masimo and Philips Licensing Agreement Brings Masimo NomoLine® Capnography and O3® Regional Oximetry to Select Philips Patient MonitorsOpen in a New Window

AMSTERDAM & IRVINE, Calif.--(BUSINESS WIRE)--Philips is integrating additional Masimo monitoring technologies into select Philips multi-parameter patient monitors.

 

Urovant Sciences Appoints James Hindman to Board of DirectorsOpen in a New Window

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Appoints James Hindman to Board of Directors

 

Biodesy Announces Corporate Name Change to BlueLight TherapeuticsOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Biodesy Inc. changed its corporate name to BlueLight Therapeutics Inc. and appointed drug discovery expert Mark Gallop, PhD, as CSO.

 

Kala Pharmaceuticals to Present at Jefferies Virtual Healthcare ConferenceOpen in a New Window

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies Virtual Healthcare Conference. Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to participate in a fireside chat on Wednesday, June 3rd, 2020 at 8:30 a.m. ET. To access a live webc

 

Tyme Technologies to Present at BIO Digital from June 8-12, 2020Open in a New Window

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present a corporate overview for 2020 at BIO Digital from June 8-12. For 2020, the BIO International Convention has transitioned to a new, virtual event format. The Company will present its corporate overview for 2020 with a special focus on multiple growth opportunities driven by advances in the science of can

 

IVERIC bio to Present at the Jefferies 2020 Healthcare ConferenceOpen in a New Window

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced that Pravin Dugel, MD will present an overview of the Company at the Jefferies 2020 Virtual Healthcare Conference.

 

Marfrig and ADM Unveil PlantPlus Foods, a Joint Venture Offering Plant-Based Food Products for Customers Across North and South AmericaOpen in a New Window

SÃO PAULO & CHICAGO--(BUSINESS WIRE)--Marfrig (B3:MRFG3 and Level 1 ADR: MRRTY) and ADM (NYSE: ADM) today announced an agreement to create PlantPlus Foods, a joint venture for the sale of plant-based food products across South American and North American markets. Marfrig, one of the world’s leading beef producers and the world’s largest beef patty producer, and ADM, a leading global nutrition company, already have a successful history working together to develop and produce sustainable, plant-b

 

VBI Vaccines Secures $50 Million Debt Financing From K2 HealthVenturesOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has entered into a debt financing facility for up to $50 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company. “This partnership with K2HV complements our recent $57.5 million equity raise, strengthening the financial position and flexibility of

 

Cortexyme to Present at the Jefferies Virtual Healthcare Conference on June 2, 2020Open in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 2:30 p.m. EDT / 11:30 a.m. PDT. A live webcast of the fireside chat will be accessible at the Investor Calendar page under

 

Pear Therapeutics to Present at the Jefferies Virtual Global Healthcare ConferenceOpen in a New Window

BOSTON & SAN FRANCISCO--(BUSINESS WIRE)--Pear Therapeutics to Present at the Jefferies Virtual Global Healthcare Conference

 

Moderna to Present at Upcoming Investor ConferencesOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to present at upcoming investor conferences.

 

Recordati Rare Diseases Inc. Announces Availability of ISTURISA® (osilodrostat) in the United StatesOpen in a New Window

LEBANON, N.J.--(BUSINESS WIRE)--Recordati Rare Diseases Inc. announced today the full availability of ISTURISA® (osilodrostat) for sale and distribution in the United States. ISTURISA was approved by the US Food and Drug Administration (FDA) on March 6, 2020, for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative. It is the first and only FDA-approved inhibitor of 11-beta-hyrdoxylase that has demonstrated normalization of

 

Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer ImmunotherapiesOpen in a New Window

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapeutics, announced today that the companies have entered into a 10-year partnership to co-develop and co-commercialize current and future therapeutic product candidates in Arcus’s pipeline. The agreement will also provide ongoing funding to support Arcus’s research and deve

 

Spectrum Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference 2020Open in a New Window

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference 2020

 

Deciphera Pharmaceuticals to Present at the Jefferies 2020 Healthcare ConferenceOpen in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies 2020 Healthcare Conference on Wednesday, June 3, 2020 at 2:00 PM ET. The conference will be held in a virtual meeting format. A live webcast of the event will be available on the “Events and Presentations” page in the “Inve

 

Biodesix Presents Numerous Research Findings at ATS, ASCO, and AACR Virtual ConferencesOpen in a New Window

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc., a leading diagnostic company in lung disease, recently published three clinical research abstracts, which reported valuable new information regarding treatment of patients in the lung cancer continuum of care. The data from these abstracts will be presented as e-posters at the virtual annual meetings of the American Thoracic Society (ATS), American Society of Clinical Oncology (ASCO), and American Association for Cancer Research (AACR). Abstract

 

Alucent Biomedical Announces First Patient Enrolled in Phase 1 Natural Vascular Scaffolding Clinical TrialOpen in a New Window

SALT LAKE CITY--(BUSINESS WIRE)-- #AlucentNVS--Alucent Biomedical has enrolled the first patients in the ACTIVATE I Phase 1 clinical trial of its Natural Vascular Scaffolding Technology for PAD.

 

Study Confirms Safety, Durability of PROCEPT BioRobotics’ Aquablation Therapy in Large Prostates at Two YearsOpen in a New Window

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #Aquablationtherapy--PROCEPT BioRobotics announces publication of WATER II study data showing Aquablation® therapy for BPH is safe, durable in large prostates at 2 years

 

Virna Therapeutics and University of Toronto Announce Licensing of Neutralizing Monoclonal Antibodies to Treat COVID-19Open in a New Window

BOSTON & TORONTO--(BUSINESS WIRE)--Virna Therapeutics and University of Toronto Announce Licensing of Neutralizing Monoclonal Antibodies to Treat COVID-19

 

Bristol Myers Squibb Receives European Commission Approval for Zeposia (ozanimod) for the Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active DiseaseOpen in a New Window

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Receives European Commission Approval for Zeposia for Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active Disease

 

Bicycle Therapeutics to Present at Upcoming Investor ConferencesOpen in a New Window

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in fireside chats at the following virtual investor conferences in June: Jefferies Global Healthcare Conference on Wednesday, June 3, 2020 at 3:00 p.m. ET Goldman Sachs 41st Annual Global Healthcare Conference on Thu

 

ChromaDex to Participate in Panel on Master Files for Dietary Supplements Hosted by the American Conference Institute (ACI) and Council for Responsible Nutrition (CRN)Open in a New Window

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced its participation in a panel discussion titled “What New Dietary Ingredient Master Files Mean for Innovation & Compliance,” hosted by the American Conference Institute (ACI) and Council for Responsible Nutrition (CRN). As the global leader in NAD+ science, ChromaDex maintains three New Dietary Ingredient (NDI) notifications from the Food & Drug Administration (FDA) for its proprietary Niagen® (nicotinamide ribos

 

Karuna Therapeutics to Present Additional Data from the Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia at the American Society of Clinical Psychopharmacology 2020 Annual MeetingOpen in a New Window

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, announced today that data from the Phase 2 clinical trial evaluating KarXT for the treatment of acute psychosis in patients with schizophrenia will be presented at the American Society of Clinical Psychopharmacology (ASCP)

 

Magellan Health to Participate in Jefferies Virtual Healthcare ConferenceOpen in a New Window

PHOENIX--(BUSINESS WIRE)--Magellan Health will participate in the Jefferies Virtual Healthcare Conference.

 

EdiGene and Immunochina Announce Research and Development Collaboration to Develop Allogeneic CAR-T Therapy for CancerOpen in a New Window

BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene, Inc., which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, and Immunochina,a company dedicated to innovative gene and cellular technology, today announced that they have formed a research and development collaboration to develop allogeneic CAR-T therapy for cancer. Under this partnership, both companies will combine EdiGene’s expertise in genome editing a

 

Doctors in Politics Launches Ambitious Effort to Send 50 Physicians to Congress In 2022Open in a New Window

NEW YORK--(BUSINESS WIRE)--Doctors in Politics launches ambitious effort to send 50 physicians to Congress in 2022, and starts by supporting 2020 doctor Congressional candidates

 

AbCellera Closes $105 Million Series B Financing to Further Advance World-Leading Antibody Drug Discovery PlatformOpen in a New Window

VANCOUVER, British Columbia--(BUSINESS WIRE)-- #antibodies--AbCellera closes US$105 million Series B financing to further advance world-leading antibody drug discovery platform.

 

Sasakawa Peace Foundation Launches Special Online Coverage of COVID-19 Featuring Original Analysis and Expert InterviewsOpen in a New Window

TOKYO--(BUSINESS WIRE)--The Sasakawa Peace Foundation (SPF) has launched a special coverage page on our website featuring the latest research into the impact of COVID-19 in Japan and around the world, interviews with experts, and additional information about SPF’s response to the pandemic. Taking advantage of our extensive network of specialists and programs around the world, this coverage aims to provide original analysis and insights as the global community faces a new reality as a result of

 

PureTech to Present at Jefferies Virtual Healthcare ConferenceOpen in a New Window

BOSTON--(BUSINESS WIRE)--PureTech to Present at Jefferies Virtual Healthcare Conference

 

Atara Biotherapeutics Announces Pricing of $175.5 Million Public OfferingOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the pricing of an underwritten public offering of 12,633,039 shares of its common stock at a price to the public of $11.32 per share and, to certain investors, pre-funde

 

Port Delivery System With Ranibizumab Shows Positive Phase III Results in Neovascular Age-Related Macular DegenerationOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the Phase III Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with neovascular or “wet” age-related macular degeneration (nAMD). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customized formulation of ranibizumab over a period of

 

Jefferies to Hold Global Coronavirus Relief Charity Day Today Dedicated to the Memory of Peg BroadbentOpen in a New Window

NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Jefferies announced that it is holding its Global Coronavirus Relief Charity Day today. The firm and its staff will contribute to global charities and relief efforts to assist those suffering from the devastation caused by the Coronavirus global pandemic and will offer investors around the world the opportunity to join these efforts by trading with Jefferies. Jefferies will dedicate this entire effort to their late CFO Peg Broadbent, who was a vic

 

Kitsbow Partners with Wake Forest Baptist Health and Dogwood Health Trust To Launch New Face Mask ProductOpen in a New Window

OLD FORT, N.C.--(BUSINESS WIRE)--Kitsbow launches new face mask product in collaboration with a team from Wake Forest Baptist Health and Dogwood Health Trust.

 

Anivive Repurposes Veterinary Drug GC376 for COVID-19 And Submits Pre-IND to FDAOpen in a New Window

LONG BEACH, Calif.--(BUSINESS WIRE)--Anivive Repurposes Veterinary Drug GC376 for COVID-19 And Submits Pre-IND to FDA

 

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent Non-Small Cell Lung CancerOpen in a New Window

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--FDA Approves Opdivo + Yervoy Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

 

TrafficCast Tracking COVID-19 Test SitesOpen in a New Window

MADISON, Wis.--(BUSINESS WIRE)--TrafficCast tracking national list of COVID-19 Test Sites. TrafficCast Incident Data Feed Includes Test Site locations and traffic restrictions

 

Sonoma Pharmaceuticals Announces Expanded Distribution Agreement with Brill International S.L. for Europe and approval of new CE Marking for Microdacyn60® Eye CareOpen in a New Window

PETALUMA, Calif.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions, is pleased to announce that it received a new CE Marking (Conformité Européenne) for its Microdacyn60® Eye Care based on Sonoma’s patented Microcyn® Technology. The formulation, marketed in the United States as Acuicyn™ Antimi

 

Eagle Pharmaceuticals to Present at June Investor ConferencesOpen in a New Window

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at two upcoming investor conferences as follows: Conference: Jefferies Virtual Healthcare Conference Date: Thursday, June 4, 2020 Time: 1:00 p.m. ET Webcast: http://wsw.com/webcast/jeff126/egrx/   Conference: William Blair Virtual 40th Annual Growth Stock Conference Date: T

 

Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers SquibbOpen in a New Window

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare”), a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in genetically defined patient populations, today announced it has entered into an exclusive, worldwide research collaboration with Bristol Myers Squibb (BMS) (NYSE:BMY). “This collaboration will help to ensure that our novel discoveries are being broadly prosecuted in the searc

 

Senseonics Launches New Remote Monitoring App for Android Users in USOpen in a New Window

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the launch of Eversense® NOW Remote Monitoring App for Android Operating System. “Now more than ever, the world relies upon remote methods of contact and support,” said Tim Goodnow, PhD, President and CEO of S

 

Intersect ENT to Present at the William Blair 40th Annual Growth Stock ConferenceOpen in a New Window

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Present at the William Blair 40th Annual Growth Stock Conference

 

Arcus Biosciences Appoints David Lacey, M.D., to Its Board of DirectorsOpen in a New Window

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that David Lacey, M.D. has joined the Company’s Board of Directors. Dr. Lacey has had a distinguished academic and highly accomplished biopharmaceutical industry career discovering and creating life-changing and critical quality of life improvement therapies for patients. “Over the years, I have had the privilege o

 

Quidel to Present Virtually at William Blair 40th Annual Growth Stock ConferenceOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the William Blair 40th Annual Growth Stock Conference to be held virtually on Wednesday, June 10, 2020. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present on that day at 10:40 a.m. Central time (8:40 a.m. Pacific time) i

 

Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded WarrantsOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of its common stock

 

Dicerna to Participate in Jefferies Virtual Global Healthcare ConferenceOpen in a New Window

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that Doug Fambrough, Ph.D., president and CEO, will present a corporate overview as part of the Jefferies Healthcare Conference.

 

Medpace Holdings, Inc. to Present at Two Upcoming Investor ConferencesOpen in a New Window

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will present at the following two investor conferences in June: Jefferies Virtual Global Healthcare Conference Date: Wednesday, June 3, 2020 Presentation: 8:30 a.m. ET Speakers: August Troendle, President & Chief Executive Officer, Jesse Geiger, Chief Financial Officer & Chief Operating Officer, Laboratory Operations, and Kevin Brady, Executive Director of Finance William Blair Virtual

 

Alpine Immune Sciences to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare ConferenceOpen in a New Window

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference

 

Xencor to Present at Upcoming Investor ConferencesOpen in a New Window

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will participate in two upcoming investor conferences: Jefferies Virtual Healthcare Conference Date: Tuesday, June 2, 2020 Presentation Time: 2:30 p.m. ET / 11:30 a.m. PT Raymond James Human Health Innovation Con

 

Alnylam to Webcast Presentations at Upcoming June Investor ConferencesOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually: Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 10:30 am ET Goldman Sachs 41st Annual Global Healthcare Conference on Thursday, June 11, 2020 at 8:00 am ET A live audio webcast of each presentation will be available on the Investors section of t

 

CORRECTING and REPLACING Moviegoers Excited to Return to Theaters If Social Distancing and Safety Guidelines Are MetOpen in a New Window

LOS ANGELES--(BUSINESS WIRE)--First paragraph, second sentence of release should read: With over 1,500 digital moviegoer respondents, 77% said they are ready to return to theaters within a few months. (instead of With over 1,500 digital moviegoer respondents, 88% said they are ready to return to theaters within a few months; 25% are willing to return immediately.) The corrected release reads: MOVIEGOERS EXCITED TO RETURN TO THEATERS IF SOCIAL DISTANCING AND SAFETY GUIDELINES ARE MET Contactless

 

CarePlus Health Plans Shares Five Steps Seniors Can Take to Protect Their Health this Hurricane SeasonOpen in a New Window

MIAMI--(BUSINESS WIRE)--CarePlus Health Plans Shares Five Steps Seniors Can Take to Protect Their Health this Hurricane Season

 

Merck Announces Third-Quarter 2020 DividendOpen in a New Window

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Third-Quarter 2020 Dividend

 

MeMD Enables Consumers, Businesses to Order COVID-19 Antibody TestingOpen in a New Window

SCOTTSDALE, Ariz.--(BUSINESS WIRE)-- #covid19--National telehealth provider MeMD offering orders for COVID-19 antibody testing through its virtual platform. Available to businesses and consumers.

 

Mauna Kea Technologies: Cellvizio® Endorsed By the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) as a Safe and Effective Diagnostic ToolOpen in a New Window

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced that the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Technology and Value Assessment Committee (TAVAC) published a review on the safety and efficacy of confocal laser endomicroscopy as a diagnostic tool for the evaluati

 

Contemporary OB/GYN® Welcomes Dr. Catherine Y. Spong as Editor-in-ChiefOpen in a New Window

CRANBURY, N.J.--(BUSINESS WIRE)-- #EditorInChief--Spong is board-certified in maternal-fetal medicine and obstetrics and gynecology.

 

Jefferies to Hold Global Coronavirus Relief Charity Day Dedicated to the Memory of Peg Broadbent on May 27thOpen in a New Window

NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Jefferies confirmed today that it will hold a Global Coronavirus Relief Charity Day tomorrow, Wednesday, May 27, 2020. The firm and its staff will contribute to global charities and relief efforts to assist those suffering from the devastation caused by the Coronavirus global pandemic and will offer investors around the world the opportunity to join these efforts by trading with Jefferies. Jefferies will dedicate this entire effort to their late C

 

MiraDx Offering COVID-19 PCR Testing for California Skilled Nursing FacilitiesOpen in a New Window

LOS ANGELES--(BUSINESS WIRE)--MiraDx Offering COVID-19 PCR Testing for CA Skilled Nursing Facilities Providing 48-Hour Turnaround Reflecting New State Guidelines

 

New Preclinical Models for NASH Provide Strong Clinical Relevance and Shortened TimelinesOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--BioDuro, LLC, a leading drug discovery and development services organization, announced today the availability of two new preclinical models for Non-alcoholic steatohepatitis (NASH) that highly resemble clinical progression of the disease and do so in a matter of 2-3 months. The models include mouse and hamster species, and manifest all the hallmarks of NASH disease, enabling drug developers to evaluate broad classes of drug targets, including metabolic inflammation

 

Consumer Fitness Survey Finds Post COVID-19, Billions in Spend Will Be Lost or Reallocated in Massive Industry TransformationOpen in a New Window

NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)--The U.S. fitness industry will be radically recast post-COVID-19, as billions of dollars in consumer spending is shifted to at-home fitness options at the expense of the health club industry. That was among the findings of an exclusive consumer survey by Harrison Co., a consumer-focused investment bank. The survey, conducted in April 2020 of approximately 1,000 fitness club users, was released in a research report today, “COVID-19 Fitness Survey.” The

 

Progenity Adds Operational Expertise to Leadership Team with Appointment of Damon Silvestry as COOOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Progenity, a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced the appointment of Damon Silvestry as Chief Operating Officer (COO). With over 15 years of strategic lab and business operations experience, Mr. Silvestry will oversee key business functions with the goal of delivering operational excellence, coordinating product teams to achieve ambitious growth targets, and dri

 

As Reopening Becomes Reality, Guidepost Solutions Focuses on Helping Businesses Safely Welcome Back Staff Via New Pandemic Support SolutionsOpen in a New Window

WASHINGTON--(BUSINESS WIRE)--Guidepost Solutions rolls out its Pandemic Support Solutions guidance, as organizations prepare to reopen their doors to employees and the public.

 

Klick Health Study in Nature Says New Homeostasis Model Could Help Doctors Detect Chronic Disease EarlyOpen in a New Window

TORONTO & NEW YORK--(BUSINESS WIRE)--New published research indicates a new model assessing the body’s homeostasis system could help physicians predict diabetes early.

 

About BioFlorida

BioFlorida represents 6,200 establishments and research organizations in the biopharmaceuticals, medical technology, healthIT and bioagriculture sectors that collectively employ 87,000 Floridians.

 

Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.

 

NEW regional sponsorship opportunities available.

Connect